§ 63-2-210 — Schedule IV.

A. Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant or depressant effect on the central nervous system: 1. Chloral betaine; 2. Chloral hydrate; 3. Ethchlorvynol; 4. Ethinamate; 5. Meprobamate; 6. Paraldehyde; 7. Petrichloral; 8. Diethylpropion; 9. Phentermine; 10. Pemoline; 11. Chlordiazepoxide; 12. Chlordiazepoxide and its salts, but not including chlordiazepoxide hydrochloride and clidinium bromide or chlordiazepoxide and water-soluble esterified estrogens; 13. Diazepam; 14. Oxazepam; 15. Clorazepate; 16. Flurazepam and its salts; 17. Clonazepam; 18. Barbital; 19. Mebutamate; 20. Methohexital; 21. Methylphenobarbital; 22. Phenobarbital; 23. Fenfluramine; 24. Pentazocine; 25. Propoxyphene; 26. Butorphanol; 27. Alprazolam; 28. Halazepam; 29. Lorazepam; 30. Prazepam; 31. Temazepam; 32. Triazolam; 33. Carisoprodol; 34. Dichloralphenazone; 35. Estazolam; 36. Eszopiclone; 37. Midazolam; 38. Modafinil; 39. Zaleplon; 40. Zolpidem; 41. Tramadol; 42. Bromazepam; 43. Suvorexant; 44. Phenazepam; 45. Etizolam; or 46. Clonazolam. B. 1. The following nonnarcotic substances, which may, under the Federal Food, Drug, and Cosmetic Act (21 U.S.C., Section 301), be lawfully sold over the counter without a prescription, are excluded from all schedules of controlled substances under this title: a. Breathe-Aid, b. BronCare, c. Bronchial Congestion, d. Bronkaid Tablets, e. Bronkaid Dual Action Caplets, f. Bronkotabs, g. Bronkolixir, h. NeoRespin, i. Pazo Hemorrhoid Ointment and Suppositories, j. Primatene Tablets, k. Primatene "Dual Action" Formula, l. Quelidrine, m. Resp, and n. Vatronal Nose Drops. 2. At the request of any person, the Director may exempt any other drug product containing ephedrine from being included as a Schedule IV controlled substance if such product: a. is labeled and marketed in a manner consistent with the pertinent OTC tentative final or final monograph issued by the FDA, and b. is manufactured and distributed for legitimate medicinal use and in a manner that reduces or eliminates the likelihood of abuse. 3. In making a determination regarding a drug product, the Director, after notice and hearing, shall consider the following: a. the history and current pattern of abuse, b. the name and labeling of the product, c. the intended manner of distribution, advertising and promotion of the product, and d. other factors as may be relevant to and consistent with the public health and safety. 4. The hearing shall be held in accordance with the Administrative Procedures Act. 5. A list of current drug products meeting exemption requirements under this subsection may be obtained from the Bureau upon written request. C. The Board of Pharmacy may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection A of this section from the application of all or any part of the Uniform Controlled Dangerous Substances Act, Section 2- 101 et seq. of this title, if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.

Legislative History

Added by Laws 1971, c. 119, § 2-210, operative Sept. 1, 1971. Amended by Laws 1976, c. 291, § 4, emerg. eff. June 17, 1976; Laws 1978, c. 171, § 1, eff. Jan. 1, 1979; Laws 1984, c. 127, § 4, eff. Nov. 1, 1984; Laws 1990, c. 271, § 2, operative July 1, 1990; Laws 1991, c. 306, § 2, emerg. eff. June 4, 1991; Laws 1995, c. 147, § 1, eff. Nov. 1, 1995; Laws 1996, c. 306, § 3, emerg. eff. June 10, 1996; Laws 2002, c. 52, § 1, eff. Nov. 1, 2002; Laws 2007, c. 248, § 3, emerg. eff. June 4, 2007; Laws 2011, c. 239, § 5, eff. Nov. 1, 2011; Laws 2012, c. 80, § 4, eff. Nov. 1, 2012; Laws 2013, c. 181, § 3, eff. Nov. 1, 2013; Laws 2014, c. 154, § 4, eff. Nov. 1, 2014; Laws 2015, c. 305, § 5; Laws 2017, c. 390, § 4, emerg. eff. June 6, 2017.